Belzutifan (Welireg)

Belzutifan at a glance

Belzutifan, known by the verified brand Welireg, blocks a protein called hypoxia-inducible factor 2 alpha, shortened to HIF-2 alpha. This protein can contribute to tumour growth. Belzutifan is usually taken once daily, with or without food. Your specialist chooses it using your diagnosis, relevant test results and overall treatment plan.

The two particularly important risks are anaemia, meaning reduced oxygen-carrying red blood cells, and hypoxia, meaning a low oxygen level in the blood. These are related concerns but are not the same measurement. You need both blood tests and oxygen checks.

Treatment may be prescribed alone or with another cancer medicine. The accompanying medicine can change monitoring, side effects and pregnancy precautions. Keep a complete list of your treatment and ask which instructions apply to each medicine. This guide does not establish local brand availability or replace your personalised plan.

How belzutifan works

HIF proteins help cells respond to changes in oxygen. In some tumours, HIF-2 alpha activity remains abnormally high and switches on signals that support cell growth and blood-vessel formation. Belzutifan interferes with that activity.

The von Hippel–Lindau, or VHL, pathway helps regulate these signals. An inherited VHL condition is relevant for some people, but not everyone prescribed belzutifan has an inherited condition. Your team interprets the diagnosis and any molecular or genetic results rather than assuming the same explanation applies to everyone.

HIF-2 alpha also influences erythropoietin, a hormone that helps the body make red blood cells. Blocking this pathway can lower red-cell production and haemoglobin, the oxygen-carrying protein inside those cells. This helps explain why monitoring for anaemia is central to treatment rather than an optional extra.

A targeted medicine can still cause serious side effects. Your team assesses tumour response separately from treatment tolerability; having few side effects does not prove treatment is ineffective, and feeling tired does not prove it is working.

How your team decides whether it is suitable

The decision considers the exact diagnosis, tumour characteristics, previous treatment, the need for other procedures, and your general health. Where relevant, genetic counselling can help explain inherited findings and what they may mean for relatives. A genetic result alone does not determine the whole treatment plan.

Tell the team about existing anaemia, blood transfusions, breathlessness, lung disease, low oxygen levels, home oxygen use, heart disease, kidney or liver problems and previous neurological or eye symptoms. Mention smoking and any planned travel to high altitude or long flights so that the team can consider your oxygen needs.

Ask what benefit treatment is intended to provide, which assessments will measure it and what would lead to a change. Some plans continue while there is benefit and side effects remain manageable; other prescribed plans have a defined duration. Do not choose a stopping date from another person's experience.

Before treatment starts

Your team checks haemoglobin and other blood results, and measures oxygen saturation before the first dose. Kidney and liver tests and other blood chemistry provide useful starting values. Explain what activity normally makes you breathless so that later changes can be recognised.

A pregnancy test is needed before starting when pregnancy is possible. Discuss reliable contraception before the first tablet: belzutifan can make some hormonal contraceptives less effective. If future parenthood matters to you, raise fertility preservation before treatment begins.

Bring all medicines, including non-prescription products, supplements, traditional remedies and occasional treatments. The pharmacist should check both products that could raise belzutifan levels and products that may work less well because of it.

If lenvatinib is prescribed with belzutifan, the current US information advises considering a baseline heart-pumping assessment, such as an echocardiogram or MUGA scan. This is a specific combination precaution, not a test every person taking belzutifan automatically requires.

Before leaving, confirm your dose, tablet count, next blood and oxygen checks, and the hospital's urgent advice arrangements. Keep any patient alert card supplied by your team available for other healthcare professionals.

How to take belzutifan

Dose and daily routine

The usual adult dose in the reviewed prescribing information is 120 mg once daily. Welireg tablets contain 40 mg, so this usual dose means three tablets taken together once a day. A prescribed reduction may mean fewer tablets. Always use your own current prescription.

Take it at approximately the same time each day, with or without food. Food does not require the fasting schedule used for some other targeted medicines. A meal or daily routine can act as a reminder, but choose an arrangement you can follow consistently.

There are specific specialist paediatric instructions in the US label for selected patients aged 12 years or older; weight can affect the dose. This adult guide should not be used to calculate a child's treatment. European information has a different paediatric scope.

Swallowing, missed doses and vomiting

Swallow tablets whole with water. Do not split, crush or chew them. If swallowing becomes difficult or a feeding tube is required, ask the specialist pharmacist for a plan before altering the tablets. No home-made dispersion method is established by this guide.

If you miss a dose, take it as soon as possible on the same day, then return to the usual daily schedule the next day. If that day has already passed, do not take extra tablets to catch up. Never double a dose. Contact your pharmacist if you are uncertain about timing.

If you vomit at any time after taking the tablets, do not repeat the dose. Take the next dose the following day. Repeated vomiting or inability to drink needs prompt advice, particularly if you also feel dizzy or pass less urine. If you accidentally take too many tablets, contact your treating hospital promptly with the pack available.

Storage and handling

Keep tablets in their original packaging, away from children, moisture and excessive heat. The US storage instruction is 20–25°C (68–77°F), with brief excursions between 15°C (59°F) and 30°C (86°F) permitted; European information has no special storage requirement. Follow your supplied pack and ask about hot-weather travel.

Do not share tablets, and keep an updated record after any dose change. Return unused medicine through your pharmacy or hospital rather than saving it for a future restart. Your team must confirm when and at what dose to restart after a treatment interruption.

Monitoring and checking whether treatment is working

Haemoglobin and oxygen saturation are checked before treatment and periodically afterwards. The prescribing information does not provide one universal weekly or monthly timetable for everyone. Your team sets the frequency using your starting results, symptoms and treatment partners. More frequent checks may be needed after a change or an abnormal result.

Blood tests can also check kidney function, liver enzymes, glucose and blood salts. These results may change without obvious symptoms. Keep appointments even when you feel well, and ask which tests are included rather than assuming every measurement is performed each time.

If home oxygen monitoring is recommended, ask which device to use, how to obtain a reliable reading, when to measure and what result should trigger urgent contact. Record symptoms as well as numbers. A pulse oximeter does not measure haemoglobin and cannot rule out anaemia. Do not let an apparently reassuring reading delay assessment of serious symptoms.

The current US label uses oxygen saturation below 88% as an example of a level requiring clinical treatment decisions. This is not a safe level to wait for at home: your team may set an earlier action threshold. A low or unexpectedly falling reading needs prompt advice, and severe symptoms need emergency care regardless of the reading.

Scans, examinations and other disease-specific tests assess benefit. Blood-count and oxygen changes mainly inform safety. A treatment pause or dose reduction can be necessary to manage toxicity; your clinician assesses tumour control separately.

Common side effects and practical care

Tiredness, dizziness and headaches

Tiredness is common, but a sudden increase may reflect anaemia or low oxygen. Report worsening exhaustion, breathlessness, light-headedness or palpitations promptly instead of assuming you simply need more sleep. Arrange help with demanding tasks and balance rest with suitable gentle activity.

Stand up carefully if you feel dizzy, and avoid driving, cycling in traffic, working at heights or using machinery when affected. Tell the team about persistent headaches. A severe unusual headache, new weakness, confusion or vision change requires urgent assessment.

Nausea and appetite changes

Use prescribed anti-sickness medicines as directed. Smaller meals and frequent sips can be easier to tolerate. Belzutifan can be taken with food, which may make fitting it into your day easier. Report ongoing nausea, weight loss or difficulty eating so that supportive treatment can be adjusted.

Do not try to treat persistent weakness with supplements alone. If appetite is poor, a dietitian can help you maintain nutrition, but blood tests are still needed to identify anaemia and other problems.

Bowel changes and discomfort

Constipation, diarrhoea and abdominal discomfort can occur. Tell the team what has changed from your normal pattern and which other medicines you take. Fluid intake, food choices and suitable activity may help, but advice should account for any fluid restriction or bowel condition.

Persistent diarrhoea, vomiting, blood in the stool, severe pain or inability to drink needs prompt assessment. Do not repeatedly increase laxatives or anti-diarrhoea medicines without guidance when these warning signs are present.

Muscle aches, swelling and weight changes

Muscle or joint discomfort can interfere with sleep and movement. Describe where it hurts and whether it is getting worse; ask which pain relief is safe with your other medicines. Gentle movement may help when you are otherwise well.

Report new ankle swelling or rapid weight gain. These can have several causes and are particularly important if you also become breathless or are taking lenvatinib. Do not simply reduce fluids or take someone else's water tablets.

Important side effects

Anaemia that needs treatment

Anaemia is common with belzutifan and can become severe. Symptoms include marked tiredness, feeling unusually cold, dizziness, breathlessness, a fast heartbeat or chest discomfort. Blood tests establish the haemoglobin level, but symptoms and your overall health also guide treatment.

Management may involve a treatment pause, a lower dose or a red-cell transfusion. The current US label uses different haemoglobin thresholds in different treatment plans: below 8 g/dL in most settings, but below 9 g/dL in a particular postsurgical combination plan; a need for transfusion is also a reason to withhold treatment. These are clinician dose-management rules, not numbers you should wait for before seeking help.

Anaemia from belzutifan is not automatically iron deficiency. Do not start iron, vitamins or injections to raise red cells without assessment. Medicines called erythropoiesis-stimulating agents, or ESAs, are sometimes considered, but the decision depends on the clinical setting and their risks. The US label says their safety for treating belzutifan-related anaemia in VHL disease has not been established; European information discusses their use under standard medical care. Your specialist should explain the options rather than treating an ESA as a routine harmless substitute for transfusion.

Low blood oxygen

Hypoxia can occur with or without obvious breathlessness. It may cause faster breathing, a fast heartbeat, unusual fatigue, agitation, confusion or difficulty doing usual activities. Contact the team immediately for new symptoms or a concerning oxygen reading. Severe breathing difficulty, collapse or confusion with marked illness requires emergency care.

Treatment may require oxygen, hospital assessment and interruption or discontinuation of belzutifan. Do not obtain oxygen or change a prescribed oxygen flow on your own unless you have a specific action plan. A normal pulse-oximeter reading does not exclude other causes of breathlessness, including anaemia or a heart problem.

Heart problems with lenvatinib

The September 2026 US information includes a specific warning about heart-pumping problems when belzutifan is used with lenvatinib. Report new or worsening breathlessness, swelling, rapid weight gain, unusual fatigue or palpitations. Chest pain, collapse or severe breathlessness is an emergency.

The team may arrange a heart scan and adjust one or both medicines. Do not assume that oxygen treatment alone will address every episode of breathlessness, and do not apply combination-study risk percentages to belzutifan taken alone.

Neurological, eye and other important changes

European information warns about bleeding in the brain or spinal region in patients with VHL-associated central nervous system haemangioblastomas, a particular type of blood-vessel tumour. If this applies to you, make sure you understand your neurological warning signs. Sudden severe headache, new weakness, speech problems, a seizure or collapse needs emergency assessment.

Report new blurred vision, flashes, a shadow across vision or sudden sight loss urgently. Serious eye events have been reported in clinical studies, and people with an underlying condition affecting the eyes may also need specialist surveillance. Do not assume a new visual change is just tiredness.

Kidney or liver blood-test changes and changes in glucose or salts can occur. Report markedly reduced urine, persistent vomiting, jaundice or severe new weakness. Your team will determine the cause and whether additional treatment or a medicine interruption is needed.

Other medicines, supplements and vaccinations

The body uses proteins called UGT2B17 and CYP2C19 to process belzutifan. Medicines that inhibit these pathways can raise belzutifan exposure and increase the risk of anaemia or hypoxia. The pharmacist checks this and may recommend closer monitoring or a prescribed adjustment. You do not need to memorise enzyme names, but you should report every medicine change.

Belzutifan can also lower the levels of certain other medicines processed through CYP3A4, making them less effective. Some combinations should be avoided. This includes a clinically important effect on hormonal contraception. Taking the medicines at different times does not necessarily prevent an interaction.

Some people process belzutifan more slowly because of inherited differences in these enzymes. If you already have pharmacogenetic results, show them to your team. The labels recommend closer attention to adverse effects in people known to have particularly slow metabolism; this does not mean everyone must arrange a private genetic test.

Ask before starting supplements, herbal products or non-prescription treatments. Discuss vaccines with the oncology team, particularly if other therapy affects immunity. The decision depends on the whole treatment plan and the type of vaccine; belzutifan's name alone does not settle the question.

Everyday life during treatment

Aim for regular meals and an amount of fluid appropriate for your health. There is no special food plan that replaces monitoring or prevents all anaemia. If you are losing weight, struggling to eat or worried about supplements, request practical dietetic advice.

Gentle activity may help fatigue, but do not push through new breathlessness or dizziness to improve fitness. Stop the activity and seek advice if symptoms change. If you smoke, ask for help to stop because smoking adds to breathing and oxygen concerns.

Work may be possible with changes to hours, physical demands and appointment arrangements. Driving should wait until dizziness, sleepiness, vision problems or other impairing symptoms have resolved. Discuss dental treatment or an operation with your cancer team so that the full medicine list and blood results can be reviewed.

Before flying or travelling to altitude, discuss oxygen levels, symptoms, anaemia and access to care with your team. This is especially important if you already need oxygen. Arrange sufficient tablets, safe storage and follow-up rather than skipping checks to fit a holiday.

A simple dosing record and reliable reminder can help. Ask for support if anxiety about oxygen readings or scans affects daily life.

Fertility, contraception, pregnancy and breastfeeding

Belzutifan can harm a developing baby. Pregnancy status should be checked before treatment. If pregnancy occurs or is suspected, contact the oncology team immediately for individual advice. Do not wait for a routine appointment.

For female patients who can become pregnant, the US label recommends effective non-hormonal contraception during treatment and for one week after the final dose. European information requires highly effective contraception during treatment and for at least one week afterwards, with additional advice because hormonal methods may fail. Do not rely on a hormonal pill, implant or other hormonal method alone without specialist contraceptive advice.

The US label also advises male patients with female partners who can become pregnant to use effective contraception during treatment and for one week after the last dose. Your team should specify suitable methods for your circumstances. Partner treatment can require longer: pembrolizumab specifies four months after its last dose for female contraception and breastfeeding, while lenvatinib specifies 30 days for female contraception. Follow the longest applicable interval.

Do not breastfeed during treatment or for at least one week after the final belzutifan dose. If another treatment is being used, follow the longest applicable restriction. Discuss a safe feeding plan before treatment or restarting breastfeeding.

Animal findings suggest fertility may be affected in males and females, and reversibility is uncertain. Discuss preservation options before treatment where relevant. Reduced fertility does not mean pregnancy cannot occur and does not replace contraception.

After treatment finishes

Continue the follow-up your team arranges, including blood counts and oxygen assessment if problems have not resolved. Ask which symptoms still require urgent contact and when other medicines that were adjusted because of interactions should be reviewed. Do not restart leftover tablets without a new instruction.

If treatment stops because of hypoxia or anaemia, the team must decide whether a later restart is safe and at what dose. Severe or recurrent problems may require stopping permanently. This is different from forgetting a daily dose.

Continue contraception and breastfeeding precautions for the documented period, including longer requirements from accompanying treatments. Keep planned tumour assessments and any follow-up needed for an inherited condition. Stopping belzutifan does not automatically end those surveillance arrangements.

Frequently asked questions